This Is MS Multiple Sclerosis Knowledge & Support Community

2021 Dec 8
Drug Discovery Laboratory, NewfvDrug, Greece
Institute for Health and Sport, Victoria University, Melbourne, Australia
Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Canada
Myelin Peptide-Mannan Conjugate Multiple Sclerosis Vaccines: Conjugation Efficacy and Stability of Vaccine Ingredient
https://pubmed.ncbi.nlm.nih.gov/34960201/

Abstract

Myelin peptide-mannan conjugates have been shown to be potential vaccines in the immunotherapy of multiple sclerosis. The conjugates are comprised from the epitope peptide and the polysaccharide mannan which transfers as a carrier the antigenic peptide to dendritic cells that process and present antigenic peptides at their surface in complex with MHC class I or class II resulting in T-cell stimulation. The conjugation of antigenic peptide with mannan occurs through the linker (Lys-Gly)5, which connects the peptide with the oxidized mannose units of mannan. This study describes novel methods for the quantification of the vaccine ingredient peptide within the conjugate, a prerequisite for approval of clinical trials in the pursuit of multiple sclerosis therapeutics. Myelin peptides, such as MOG35-55, MBP83-99, and PLP131-145 in linear or cyclic form, as altered peptide ligands or conjugated to appropriate carriers, possess immunomodulatory properties in experimental models and are potential candidates for clinical trials.

This abstract makes no sense to me. Vaccinate against what and what basis?

Scott1 wrote: ↑Wed Dec 29, 2021 6:57 pm This abstract makes no sense to me. Vaccinate against what and what basis?

The full paper is freely available.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8708491/

From the paper’s introduction, the goal of the vaccines appears to be to increase tolerance and shift the T-cell response from Th1 to Th2.

Ok. The article makes more sense.
In essence, they deliver a carbohydrate, isolated from wheat, to one of the myelin proteins. This is then presented to a dendritic cell which instructs a T cell. The new protein stimulates toll like receptor 4 so the T cell then follows a non inflammatory pathway rather than an inflammatory one. They argue it should work as a similar process has been successfully followed for some anti-cancer treatments.
The approach is interesting because it addresses the issue of why the CD4+ T cells in MS are autoreactive and aggressive by focussing on dendritic cells.
If it worked it would kiss goodnight to T and B cell therapies.
Obviously a very long way to go yet.
Thanks for the whole article.